ClinicalTrials.gg
Active, not recruitingNCT05049798PsABIOndUpdated Nov 3, 2026

A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical Practice

An observational study in Arthritis, Psoriatic, sponsored by Janssen Pharmaceutica N.V., Belgium. Active, not recruiting at 155 sites in 20 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Janssen Pharmaceutica N.V., Belgium (part of Johnson & Johnson) · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,314
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 37 studies in Arthritis, Psoriatic by Johnson & Johnson — 5 open to participants now, 13 under way, 5 of them phase 3. Arthritis, Psoriatic · Johnson & Johnson.

Enrollment
3rd of 12
1,314 · median 681
Started
2021
with 6 others
Observational
12 of 37
2 open now
Primary completion
2027-08
later than 7 of 12 live
Registered
26th of 37
by date

Among the 37 studies in Arthritis, Psoriatic by Johnson & Johnson, this one is the 3rd largest by enrollment of the 12 observational ones that give a count, is one of 7 that started in 2021, is one of 12 observational ones, reaches primary completion later than 7 of the 12 other live ones, and was the 26th registered.

Arthritis, Psoriatic

602 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

5 of the 37 studies in Arthritis, Psoriatic by Johnson & Johnson are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 89 Arthritis, Psoriatic studies recruiting now, 52 (58%) set no upper age limit and 28 (31%) stop at 75 or younger; 12 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Arthritis, Psoriatic by Johnson & Johnson, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate treatment persistence with guselkumab and interleukin-17 inhibitor (IL-17i) initiated at enrollment into this study (PsABIOnd).

Read the detailed description

Psoriatic arthritis (PsA) is a seronegative inflammatory spondylarthritis associated with psoriasis (PsO), which can cause pain and swelling in the joints, sausage-shaped swelling of the fingers and toes (dactylitis), inflammation of the muscle- or tendon insertions at adjacent bone (enthesitis), as well as raised red patches or various other expressions of psoriasis on the skin. Guselkumab (TREMFYA) is a fully human immunoglobulin G1 lambda (IgG1) monoclonal antibody (mAb) that binds to the p19 subunit of human interleukin (IL) 23 with high specificity and affinity, blocking IL-23 binding. Binding of guselkumab to the IL-23p19 subunit blocks the subsequent binding of extracellular IL-23 to the cell surface IL-23 receptor, inhibiting IL-23 specific intracellular signaling and subsequent activation and cytokine production. Participants with confirmed diagnosis of PsA who are starting guselkumab or any marketed interleukin-17 inhibitor (IL-17i) as a first, second, third, or fourth line of PsA biologic therapy per standard clinical practice will be enrolled in the main study. The aim of main study is to document the use of guselkumab and approved IL-17i therapies in routine clinical practice in patients with PsA who are starting guselkumab or an IL-17i as a first, second, third, or fourth line of biologic disease-modifying antirheumatic drugs (bDMARD) therapy. The overall duration of the main study, including recruitment and follow-up, is expected to be about 6 years. Participants who are starting guselkumab or an IL-17i treatment per routine clinical practice in the main study, and who meet the selection criteria for both the main study and substudy, will be consecutively offered entry into the substudy (a select number) at the time of enrollment into the main study. The substudy aims to collect additional data, continuously or with increased frequency, on the impact of guselkumab or IL-17i on patient mood, physical activity, sleep disturbance, disease symptoms, and health-related quality-of-life (HRQoL). Total duration of the substudy will be approximately 26-30 weeks consisting of a pre-treatment period of up to 14 days before the first dose of guselkumab or IL-17i in the main study and a 24-week (plus [+] up to 4 weeks follow-up) observation period.

03

Conditions studied

  • Arthritis, Psoriatic

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

The study population consists of participants initially treated for Psoriatic Arthritis (PsA) with guselkumab or interleukin-17 inhibitor (IL-17i) per routine clinical practice in accordance with clinical guidelines.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Main study:

  • Have a confirmed diagnosis of PsA as determined by a rheumatologist with reference to Classification criteria for Psoriatic Arthritis (CASPAR)
  • Start guselkumab or any approved interleukin-17 inhibitor (IL-17i) as a first, second, third, or fourth line of biologic disease-modifying antirheumatic drugs (bDMARD) therapy for the indication of PsA as part of standard clinical practice (according to local label, local regulations, and/or reimbursement requirements) at the time of enrollment into the observational study or within a maximum of 2 months after the initial baseline visit or after repeated baseline data collection
  • Sign a participation agreement/ form (ICF) allowing data collection and source data verification in accordance with local requirements
  • Able to read, understand, and intend to comply with completion of all Electronic patient-reported outcome (ePRO) instruments
  • The treatment decision must be taken by the participating rheumatologist prior to, and independently of the participant's inclusion into the study, following clinical practice in accordance with local and overarching guidelines and local regulations

Substudy:

  • Must sign the substudy ICF allowing data collection in accordance with local requirements
  • Is scheduled to receive guselkumab or IL-17i, per routine clinical practice, in the main study
  • Currently using or is willing to use wearables and/or commercial applications to track their disease within the course of their normal daily activities

Exclusion criteria

Exclusion Criteria:

Main study:

  • Start guselkumab or an IL-17i therapy as fifth or further line of biologic treatment
  • Have already taken a specific IL-17i or IL-23i treatment and are planning on re-taking that specific treatment again
  • Unwilling or unable to participate in long-term data collection
  • Received an drug (including investigational vaccines) or used an invasive investigational medical device within 30 days before the start of the study (that is, signing of )
  • Currently enrolled in any interventional study or any Janssen-sponsored observational clinical study (contemporary participation into observational studies or registries not sponsored by Janssen is acceptable)

Substudy:

  • Have an insufficient command of language to interact effectively with the smartphone application, in the opinion of the investigator at each site
  • Any condition for which, in the opinion of the investigator, participation would not be in the best interest of the patient (example, compromise the well-being) or that could prevent, limit, or confound assessment
  • Unwilling or unable to comply with substudy assessments
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,314 participants (actual)
Patient registry
No

Groups and cohorts

  • Cohort 1: Guselkumab

    Data as available from participant's source medical records will be collected for adult participants with a confirmed diagnosis of Psoriatic Arthritis (PsA) who are starting guselkumab as a first, second, third, or fourth line of PsA biologic therapy either as monotherapy or with other medications per routine clinical practice in main study. Participants who meet the selection criteria for both the main study and substudy, will be consecutively offered to be enrolled into the substudy at the time of enrollment into the main study.

    Drug: Guselkumab

  • Cohort 2: Interleukin-17 inhibitor (IL-17i)

    Data as available from participant's source medical records will be collected for adult participants with a confirmed diagnosis of PsA who are starting IL-17i as a first, second, third, or fourth line of PsA biologic therapy either as monotherapy or with other medications per routine clinical practice in main study. Participants who meet the selection criteria for both the main study and substudy, will be consecutively offered to be enrolled into the substudy at the time of enrollment into the main study.

    Drug: IL-17i

Interventions

  • Participants will not receive any intervention as a part of this study. Participants who are initiating the treatment with guselkumab, will be observed according to standard clinical practice.

    Also known as: TREMFYA

  • DrugIL-17i

    Participants will not receive any intervention as a part of this study. Participants who are initiating the treatment with IL-17i, will be observed according to standard clinical practice.

06

What researchers measure

Primary outcomes

  1. The Start and Stop Date of Guselkumab, as Applicable, For Each Participant

    The start and stop date, (first and last administration date, respectively) of guselkumab, as applicable, for each participant will be collected to document treatment persistence.

    Time frame: Up to 39 months

  2. The Start and Stop Date of Interleukin-17 Inhibitor (IL-17i), as Applicable, For Each Participant

    The start and stop date (first and last administration date respectively) of IL-17i, as applicable, for each participant will be collected to document treatment persistence.

    Time frame: Up to 39 months

Secondary outcomes

  1. Change from Baseline in 66 and 68 Joint Counts for Swelling and Tenderness, Respectively

    Change from baseline in 66 and 68 joint counts for swelling and tenderness, respectively will be reported. Joints assessed include the distal interphalangeal, proximal interphalangeal, and metacarpophalangeal joints of the hands; the wrist, elbow, shoulder, acromioclavicular, sternoclavicular, temporomandibular, hip (excluded for swelling), knee, ankle, and midtarsal joints; and the metatarsophalangeal and proximal interphalangeal joints of the feet.

    Time frame: Baseline up to 39 months

  2. Change from Baseline in Rheumatologist's Global Assessment of Disease Activity-Psoriatic Arthritis (PGA-PsA)

    The PGA-PsA will be documented using a Visual Analogue Scale (VAS) that ranges from "no PsA activity" (0 Millimeter \[mm\]) to "extremely active PsA" (100 mm).

    Time frame: Baseline up to 39 months

  3. Change from Baseline in Assessment of Dactylitis

    The presence of and total number of digits of the hands and feet (that is, 0 to 20) with dactylitis will be documented.

    Time frame: Baseline up to 39 months

  4. Change from Baseline in Assessment of Enthesitis using Leeds Enthesitis Index (LEI)

    The presence and a score of enthesitis will be documented using the LEI to evaluate the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: the lateral epicondyles (left and right), medial femoral condyles (left and right), and Achilles tendon insertions (left and right).

    Time frame: Baseline up to 39 months

  5. Change from Baseline in Nail Involvement

    Nail involvement will be documented by recording the total number of nails of the hands and feet (that is, 0 to 20) with psoriatic nail changes.

    Time frame: Baseline up to 39 months

  6. Change from Baseline in Body Surface Area (BSA) Psoriasis (PSO) Skin Involvement

    The BSA score indicates the surface area of the participant's body effected by psoriasis.

    Time frame: Baseline up to 39 months

  7. Change from Baseline in C-reactive Protein (CRP)

    Change from baseline in CRP will be reported.

    Time frame: Baseline up to 39 months

  8. Change from Baseline in Minimal Disease Activity (MDA)/ Very Low Disease Activity (VLDA)

    Change from Baseline in MDA/VLDA will be reported.

    Time frame: Baseline up to 39 months

  9. Change from Baseline in Clinical Disease Activity Index for Psoriatic Arthritis (cDAPSA/DAPSA)

    DAPSA assesses the joint domain of PsA and is derived from the sum of the following components: Participant's assessment of pain on VAS (in centimeters), Participant's Global Assessment of Disease Activity on VAS (in centimeters), 66 and 68 joint counts for swelling and tenderness, respectively.

    Time frame: Baseline up to 39 months

  10. Response as a Measure of Clinical Improvement in cDAPSA/DAPSA

    Response is defined as a clinical improvement in cDAPSA/DAPSA. DAPSA assesses the joint domain of PsA and is derived from the sum of the following components: Participant's assessment of pain on VAS (in centimeters), Participant's Global Assessment of Disease Activity on VAS (in centimeters), 66 and 68 joint counts for swelling and tenderness, respectively.

    Time frame: Up to 39 months

  11. Start and Stop Dates of All Treatments and the Sequence of Treatment Lines

    Start and stop dates of all treatments and the sequence of treatment lines will be reported.

    Time frame: Up to 39 months

  12. Percentage of Participants with Adverse Events (AEs)

    An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.

    Time frame: Up to 39 months

  13. BSA PSO Skin Involvement

    The BSA score indicates the surface area of the participant's body affected by psoriasis.

    Time frame: Up to 39 months

  14. Rheumatic Disease Comorbidity Index

    Number of comorbid medical conditions of the study participants for the Rheumatic Disease Comorbidity Index will be reported.

    Time frame: Up to 39 months

  15. Change from Baseline in Fibromyalgia Rapid Screening Tool (FiRST)

    FiRST will be used to help determine whether participants have chronic widespread pain or fibromyalgia syndrome at entry into the study. The FiRST is a validated questionnaire consisting of a combination of 6 items that can detect chronic widespread pain.

    Time frame: Baseline up to 6 months

  16. Change from Baseline in European Quality of Life (EuroQoL) 5-Dimensions 5-Levels Questionnaire (EQ-5D-5L)

    The EQ-5D-5L is a standardized instrument for use as a measure of health outcome, primarily designed for self-completion by respondents. The EQ-5D-5L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each of the 5 dimensions is divided into 5 levels of perceived problems, where Level 1: no problem, Level 2: slight problems, Level 3: moderate problems, Level 4: severe problems and Level 5: extreme problems.

    Time frame: Baseline up to 39 months

  17. Change from Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI)

    The functional status of the participants will be assessed by the HAQ-DI. This 20-question self-administered instrument assesses the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). The derived HAQ-DI ranges from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area.

    Time frame: Baseline up to 39 months

  18. Change from Baseline in Psoriatic Arthritis Impact of Disease-12 (PsAID-12)

    PsAID-12 is a validated, self-administered questionnaire that assesses the impact of PsA on participants' lives. It consists of 12 questions, each answered using a numerical rating scale. Questions related to pain, skin problems, work and/or leisure activities, discomfort, embarrassment and/or shame, social participation, and anger, fear, and uncertainty, and depression are scored from 0 (none) to 10 (extreme), functional capacity and sleep disturbance are scored from 0 (no difficulty) to 10 (extreme difficulty) and coping is scored from 0 (very well) to 10 (very poorly).

    Time frame: Baseline up to 39 months

  19. Change from Baseline in Patient Global Disease Activity Visual Analog Scale (VAS) Scores

    The Patient Global Disease Activity VAS is a self-administered assessment with scores ranging from "very well" (0 mm) to "very poor" (100 mm) that assesses disease activity over the past week.

    Time frame: Baseline up to 39 months

  20. Change from Baseline in Pain VAS Score

    The pain VAS is a self-administered assessment of average pain during the past week. The scale ranges from "no pain" (0 mm) to "the worst possible pain" (100 mm).

    Time frame: Baseline up to 39 months

  21. Change from Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)

    BASDAI consists of a 1 through 10 scale (1 being no problem and 10 being the worst problem) which is used to answer 6 questions pertaining to the 5 major symptoms of ankylosing spondylitis: fatigue, spinal pain, joint pain/swelling, areas of localized tenderness (also called enthesitis, or inflammation of tendons and ligaments), morning stiffness duration, morning stiffness severity.

    Time frame: Baseline up to 39 months

  22. Change from Baseline in Ankylosing Spondylitis Disease Activity Score - C-reactive protein (ASDAS-CRP)

    The ASDAS-CRP is a composite of 5 disease activity variables with only partial overlap. The 4 self-reported items included in this index are back pain (VAS), duration of morning stiffness, peripheral pain/swelling, and participant global assessment of disease activity; these are combined with the CRP value.

    Time frame: Baseline up to 39 months

  23. Change from Baseline in Dermatology Life Quality Index (DLQI)

    The DLQI is a dermatology-specific, validated, 10-question quality of life instrument used to measure the impact of skin disease on the quality of life of an affected person. Each question will address how much the participant's skin problem has affected their life and is scored as: 3 = very much, 2 = a lot, 1 = a little, 0 = not at all, or not relevant.

    Time frame: Baseline up to 39 months

  24. Change from Baseline in Patient Acceptable Symptom State (PASS)

    The PASS measures the level of symptoms beyond which participants consider themselves well. The PASS addresses the concepts of low disease activity, partial remission in symptoms, and well-being.

    Time frame: Baseline up to 39 months

  25. Change from Baseline in Work Productivity and Activity Impairment Questionnaire: Psoriatic Arthritis (WPAI: PsA)

    The WPAI: PsA is a validated, self-administered questionnaire that assesses work and activity impairment during the past 7 days. The WPAI: PsA produces 4 types of scores: absenteeism (work time missed), presenteeism (impairment at work/reduced on-the-job effectiveness), work productivity loss (overall work impairment/absenteeism plus presenteeism), and activity impairment. The WPAI: PsA outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity, that is, worse outcomes.

    Time frame: Baseline up to 39 months

  26. Change from Baseline in Treatment Satisfaction Questionnaire for Medication-9 (TSQM-9)

    TSQM-9 is a 9-item, validated, self-administered instrument used to assess participant's satisfaction with medication. The three domains assessed are effectiveness, convenience, and side effects of the medication.

    Time frame: Baseline up to 39 months

  27. Number of Participants Switching or Stopping Treatment

    Number of Participants switching or stopping treatment (including reasons for discontinuation) will be reported.

    Time frame: Up to 39 months

07

Study locations

155 sites

Showing the first 100 of 155 sites across 20 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Siebert S, Behrens F, Lubrano E, Martin N, Sharaf M, Contre C, Theander E, Queiro R, Zimmermann M, Gossec L. PsABIOnd Study and eDaily Substudy Design: Long-Term Effectiveness and Safety of Guselkumab and IL-17 Inhibitors in Routine Clinical Practice in Patients with Psoriatic Arthritis. Rheumatol Ther. 2023 Apr;10(2):489-505. doi: 10.1007/s40744-022-00518-w. Epub 2022 Dec 30. PubMed 36585602 ↗

Individual participant data

Plan to share: No

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2021 (actual). Primary completion is estimated for Aug 2027, 71 months after the start.

Of 52 industry-sponsored observational studies under Arthritis, Psoriatic, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 63. This study's planned 71 months is above that.

Counting every sponsor, half of 129 studies reached it within 47 months; a quarter within 28 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2021
First posted
Sep 20, 2021
StartActual
Aug 25, 2021
Primary completionEst.
Aug 1, 2027
CompletionEst.
Aug 2, 2027
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and site details
2 updates, last Nov 3, 2026
Show all 2 updates
  1. Nov 3, 2026
    Minor edits only
    + 2 other changes: verification date and site details
  2. Sep 25, 2026
    Minor edits only
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05049798
Responsible party
Sponsor
First posted
Sep 20, 2021
Start date
Aug 25, 2021
Primary completion
Aug 1, 2027 (estimated)
Completion
Aug 2, 2027 (estimated)
Last update
Nov 3, 2026

Study contacts

Janssen Pharmaceutica N.V., Belgium Clinical Trial
study director · Janssen Pharmaceutica N.V., Belgium

Oversight

Data monitoring committee
No
FDA-regulated drug
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion